DURECT (NASDAQ:DRRX) Posts Earnings Results, Misses Expectations By $0.12 EPS

DURECT (NASDAQ:DRRX) released its quarterly earnings results on Wednesday. The specialty pharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($0.12), Zacks reports. The business had revenue of $2.30 million for the quarter, compared to the consensus estimate of $6.91 million. DURECT had a negative net margin of 198.58% and a negative return on equity of 300.62%.

DURECT Price Performance

Shares of DURECT stock remained flat at $0.81 during trading hours on Thursday. The stock had a trading volume of 59,654 shares, compared to its average volume of 53,861. The stock has a market capitalization of $25.02 million, a PE ratio of -1.32 and a beta of 0.91. DURECT has a 1 year low of $0.70 and a 1 year high of $1.88. The stock’s 50-day moving average is $0.80 and its two-hundred day moving average is $1.01.

Analyst Ratings Changes

DRRX has been the topic of several research analyst reports. StockNews.com began coverage on shares of DURECT in a report on Thursday. They set a “sell” rating on the stock. HC Wainwright restated a “neutral” rating on shares of DURECT in a report on Thursday.

About DURECT

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.